G. N. Grantham

Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

R. Schilsky, J. Krauss, C. Calfa, 2022, JCO precision oncology.

Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.

R. Schilsky, F. Meric-Bernstam, E. Garrett-Mayer, 2022, JCO precision oncology.

Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.

R. Schilsky, E. Yang, E. Burgess, 2023, JCO precision oncology.

Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.

M. Maitland, R. Schilsky, C. Drescher, 2023, JCO precision oncology.

Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study

R. Schilsky, Rui Li, A. Alva, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study

R. Schilsky, A. Alva, C. Calfa, 2024, JCO Precision Oncology.

Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.

R. Schilsky, C. Calfa, K. Gogineni, 2024, JCO precision oncology.

Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.

R. Schilsky, F. Meric-Bernstam, M. von Mehren, 2023, JCO precision oncology.